Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 3500
Single User License Price INR 241150
Corporate User License Price USD 10500
Corporate User License Price INR 723450
Site License Price USD 7000
Site License Price INR 482300
Request a Quote

Report Title

Dual-Specificity-Tyrosine-Phosphorylation-Regulated-Kinase-1A-(Serine/Threonine-Kinase-MNB-or-MNB/DYRK-Protein-Kinase-or-Dual-specificity-YAK1-Related-Kinase-or-HP86-or-Protein-Kinase-Minibrain-Homolog-or-DYRK1A-or-EC-2.7.12.1)-Pipeline-Review-H2-2017

Quote Request for License Type
License Type Price  
Single User License USD 3500
Site License USD 7000
Enterprise Wide License USD 10500
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Dual-Specificity-Tyrosine-Phosphorylation-Regulated-Kinase-1A-(Serine/Threonine-Kinase-MNB-or-MNB/DYRK-Protein-Kinase-or-Dual-specificity-YAK1-Related-Kinase-or-HP86-or-Protein-Kinase-Minibrain-Homolog-or-DYRK1A-or-EC-2.7.12.1)-Pipeline-Review-H2-2017


Quote Request for License Type
License Type Price  
Single User License USD 3500
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Dual-Specificity-Tyrosine-Phosphorylation-Regulated-Kinase-1A-(Serine/Threonine-Kinase-MNB-or-MNB/DYRK-Protein-Kinase-or-Dual-specificity-YAK1-Related-Kinase-or-HP86-or-Protein-Kinase-Minibrain-Homolog-or-DYRK1A-or-EC-2.7.12.1)-Pipeline-Review-H2-2017

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Dual-Specificity-Tyrosine-Phosphorylation-Regulated-Kinase-1A-(Serine/Threonine-Kinase-MNB-or-MNB/DYRK-Protein-Kinase-or-Dual-specificity-YAK1-Related-Kinase-or-HP86-or-Protein-Kinase-Minibrain-Homolog-or-DYRK1A-or-EC-2.7.12.1)-Pipeline-Review-H2-2017



Executive Summary

Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1)-Pipeline Review, H2 2017

Summary

Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) pipeline Target constitutes close to 10 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes. The latest report Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A-Pipeline Review, H2 2017, outlays comprehensive information on the Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1)-Dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) is an enzyme that is encoded by the DYRK1A gene. DYRK1A autophosphorylates on tyrosine serine and threonine residues but phosphorylate substrates only on serine or threonine residues. It plays a significant role in a signaling pathway regulating cell proliferation and involved in brain development. The molecules developed by companies in Preclinical and Discovery stages are 4 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Genetic Disorders, Oncology and Metabolic Disorders which include indications Alzheimer's Disease, Down Syndrome, Colon Cancer, Dementia, Depression, Glioblastoma Multiforme (GBM), Lung Cancer, Pancreatic Cancer, Parkinson's Disease, Post-Traumatic Stress Disorder (PTSD), Prostate Cancer and Type 1 Diabetes (Juvenile Diabetes).

Furthermore, this report also reviews key players involved in Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1)

The report reviews Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) targeted therapeutics and enlists all their major and minor projects

The report assesses Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1)-Overview

Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1)-Companies Involved in Therapeutics Development

Carna Biosciences Inc

Felicitex Therapeutics

ManRos Therapeutics

NeuroNascent Inc

Pharmasum Therapeutics AS

Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1)-Drug Profiles

FX-9847-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Harmine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NNI-351-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PST-900-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to inhibit DYRK1A for Alzheimer's and Down Syndrome-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit DYRK1A for Alzheimer's Disease and Down Syndrome-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit DYRK1A for Neurodegenerative Diseases-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Dyrk1a for Alzheimer's Disease and Down syndrome-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit DYRK1A for Alzheimer's Disease and Down Syndrome-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit DYRK1A for Glioblastoma Multiforme-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1)-Dormant Products

Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1)-Discontinued Products

Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1)-Product Development Milestones

Featured News & Press Releases

Feb 05, 2015: Neuronascent Announces Expanded Patent Coverage in Russia for Its Down Syndrome Therapeutics

Mar 20, 2013: BIO5-TGen Collaboration Focused On Drug Development For Alzheimer's Disease

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Top 10 Indications, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

List of Tables

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indication, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Number of Products under Investigation by Universities/Institutes, H2 2017

Products under Investigation by Universities/Institutes, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pipeline by Carna Biosciences Inc, H2 2017

Pipeline by Felicitex Therapeutics, H2 2017

Pipeline by ManRos Therapeutics, H2 2017

Pipeline by NeuroNascent Inc, H2 2017

Pipeline by Pharmasum Therapeutics AS, H2 2017

Dormant Projects, H2 2017

Discontinued Products, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Carna Biosciences Inc

Felicitex Therapeutics

ManRos Therapeutics

NeuroNascent Inc

Pharmasum Therapeutics AS

Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) Therapeutic Products under Development, Key Players in Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) Therapeutics, Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) Pipeline Overview, Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) Pipeline, Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) Pipeline Assessment


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person